The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.

Immunotherapy plays an important role in cancer treatment. Biomarkers that can predict response, including tumor-infiltrating lymphocytes (TILs), are in the spotlight of many studies. This cohort study was designed to evaluate the role of CD4+ and CD8+ TILs as predictive factors for response to anti PD-1 treatment in patients with metastatic non-small cell lung cancer (NSCLC) or metastatic melanoma.

Post-irradiation angiosarcoma of the breast: clinical presentation and outcome in a series of six cases.

Angiosarcoma of the breast represents 1% of all soft tissue breast tumors. With breast-conserving therapy (BCT) as standard in the last three decades, a new type of angiosarcoma has been reported: post-irradiation angiosarcoma (PIAS). A recent study based on the SEER database found an absolute risk for PIAS of seven per 100,000 person-years for BCT patients.